GlassScriptPhysician profile
Aleksandra Kraeher
NPI 1790744910
$16,819.99
in general payments reported to CMS, 2019-2025
50 companies · $2,803 in 2025
The $2,803 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,945 · 2020: $1,584 · 2021: $2,276 · 2022: $2,391 · 2023: $2,281 · 2024: $2,541 · 2025: $2,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,564 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,564.32 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,851.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,516.87 | 2019-2025 | Evenity, Prolia, Tepezza |
| Astrazeneca Pharmaceuticals LP | $1,004.90 | 2019-2022 | |
| Lilly USA, LLC | $990.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $900.06 | 2019-2025 | |
| Mannkind Corporation | $864.96 | 2019-2025 | Afrezza |
| Medtronic, INC. | $618.77 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $594.95 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $468.02 | 2024-2025 | Strensiq |
| Stryker Corporation | $457.15 | 2019-2023 | Anchorage |
| Currax Pharmaceuticals LLC | $440.21 | 2020-2025 | Contrave, Nexletol, Nexlizet |
| Bayer Healthcare Pharmaceuticals INC. | $429.13 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.22 | 2019-2024 | Synjardy, Jardiance |
| Tandem Diabetes Care, INC. | $411.38 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $398.94 | 2024 | Ilet Bionic Pancreas |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandra Kraeher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.